Market Overview

UPDATE: Citigroup Lowers PT on Abbott Laboratories Following In-Line 2Q13 Results

Related ABT
Time To Buy Mylan's Clear Path To EPS Upside, JP Morgan Says
Goldman Is Downgrading Abbott Laboratories

In a report published Friday, Citigroup analyst Matthew J. Dodds reiterated a Sell rating on Abbott Laboratories (NYSE: ABT), and lowered the price target from $33.00 to $31.00.

In the report, Citigroup noted, “ABT's sales came in a bit light for the 2nd straight quarter and were in line with our forecast. Comparisons do get a bit easier in 2H but management's expectations of improvement nearly across the board still appear aggressive and likely need to be at least met in order to maintain the current premium valuation.”

Abbott Laboratories closed on Thursday at $35.70.

Latest Ratings for ABT

Nov 2015Goldman SachsDowngradesBuyNeutral
Oct 2015BarclaysUpgradesEqual-weightOverweight
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Citigroup Matthew J. DoddsAnalyst Color Price Target Analyst Ratings


Related Articles (ABT)

Get Benzinga's Newsletters